share_log

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga ·  Feb 22 08:05

Gainers

  • Agile Therapeutics (NASDAQ:AGRX) stock rose 82.4% to $1.81 during Thursday's pre-market session. The company's market cap stands at $5.3 million.
  • Venus Concept (NASDAQ:VERO) stock rose 72.95% to $2.11. The market value of their outstanding shares is at $11.6 million.
  • Monopar Therapeutics (NASDAQ:MNPR) stock rose 71.91% to $0.98. The market value of their outstanding shares is at $14.5 million.
  • Ocular Therapeutix (NASDAQ:OCUL) shares increased by 21.27% to $9.12. The market value of their outstanding shares is at $1.0 billion.
  • Indivior (NASDAQ:INDV) shares increased by 16.74% to $20.43. The market value of their outstanding shares is at $2.7 billion. As per the press release, Q4 earnings came out today.
  • Apyx Medical (NASDAQ:APYX) shares increased by 15.3% to $2.33. The company's market cap stands at $80.6 million.

Losers

  • Synaptogenix (NASDAQ:SNPX) shares fell 20.9% to $0.21 during Thursday's pre-market session. The market value of their outstanding shares is at $4.2 million.
  • Motus GI Hldgs (NASDAQ:MOTS) shares declined by 18.19% to $0.9. The company's market cap stands at $1.3 million.
  • Chemomab Therapeutics (NASDAQ:CMMB) shares decreased by 9.69% to $0.61. The market value of their outstanding shares is at $6.8 million.
  • Agape ATP (NASDAQ:ATPC) shares fell 8.86% to $0.32. The company's market cap stands at $24.5 million.
  • China Pharma Holding (AMEX:CPHI) stock decreased by 7.91% to $0.09. The market value of their outstanding shares is at $4.8 million.
  • Cadrenal Therapeutics (NASDAQ:CVKD) stock declined by 7.84% to $0.68. The market value of their outstanding shares is at $8.8 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment